Skip to content

Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease.

Chonglei Fu, Xuehui Li, Xiaoxing Liu, Yongbo Zheng, Xiangxian Ma, Bo Zhang, Si Chen, Lingming Hu, Sizhen Su, Xiaokun Wang, Jie Sun, Qingqing Yin, Yumei Wang, Xiaolong Fu, Yanping Bao, Yanxue Xue, Tao Xin, Lin Lu, Guichang Zou

Translational neurodegeneration July 25, 2025 DOI: 10.1186/s40035-025-00498-1 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Keywords Alzheimer's disease Challenges Molecular insights Psychoactive substances Therapeutic potential Combat neurodegeneration Improve brain health Novel strategies These compounds New path
Citations 2
Key findings Psychoactive substances show potential for enhancing learning and cognitive performance and may have neurorestorative functions in Alzheimer's disease.

Abstract

Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health systems. Despite extensive research, effective treatments to stop neurodegeneration or promote neuronal regeneration in AD remain elusive. Psychoactive substances as modulators of neurophysiological functions, have received increased attention in research. The main psychoactive agents, such as central nervous system depressants and stimulants, cannabinoids, psychedelics, opioids and ketamine, are being explored for their abilities to enhance learning and cognitive performance and potential neurorestorative functions. In this paper, we review the molecular mechanisms and therapeutic potential of psychoactive substances in AD, in the aim to guide future research directions.